The prognosis for MSI-H tumors tends to be better compared to MSS tumors. MSI-H colorectal cancers, for example, often have a better overall survival rate. However, the response to conventional treatments may vary. MSI-H tumors are generally less responsive to certain types of chemotherapy but may respond exceptionally well to immunotherapy.
